<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> AP891106-0284 </DOCNO><FILEID>AP-NR-11-06-89 2106EST</FILEID><FIRST>r f BC-Colgate-Vipont 1stLd-Writethru f0088 11-06 0345</FIRST><SECOND>BC-Colgate-Vipont, 1st Ld-Writethru, f0088,0353</SECOND><HEAD>Colgate to Acquire Vipont Pharmaceutical</HEAD><HEAD>Eds: SUBS last graf to CORRECT that earnings figures are for yearended Sept. 30, 1988, sted this year.</HEAD><DATELINE>FORT COLLINS, Colo. (AP) </DATELINE><TEXT>   Colgate-Palmolive Co. will acquireVipont Pharmaceutical Inc. for about $94 million, enabling Colgateto strengthen its oral hygiene product line, the companiesannounced Monday.   The merger agreement calls for the Fort Collins-based Vipont tosell Colgate all of its outstanding common shares, for $14 pershare.   Vipont also will spin off to its shareholders on Dec. 1 a totalof 65 percent of the outstanding shares of Vipont Research LabsInc., Vipont's research subsidiary. Part of the agreement calls forColgate to have exclusive rights to distribute Vipont Research'speriodontal treatment products. Colgate also will acquire a 10percent equity interest in Vipont Research under the agreement,according to the announcement by Vipont.   ``Through Vipont's patented technology, Colgate can furtherbuild its global leadership in oral care in a number of strategicways,'' said Reuben Mark, Colgate chairman and chief executiveofficer. ``Specifically, Colgate has positioned itself as a leaderin anti-cavity, anti-tartar, and now with Vipont, anti-plaquetechnology.''   Colgate makes one of the world's top-selling toothpastes andalso sells a full line of toothbrushes, mouth rinses andprofessional dental products. Vipont's anti-plaque toothpaste andmouth rinse products are sold under the Viadent brand name.   ``The Vipont technology is in the forefront of perio products,''said Lawrence L. Frederick, president and chief executive officerof Vipont Pharmaceutical. ``By becoming part of Colgate, thistechnology will now receive the marketing and financial resourcesto become truly global.''   Closing of the tender offer hinges on Colgate receiving tendersof at least 65 percent of the outstanding stock of VipontPharmaceutical.   Following the close of the tender offer, a Colgate subsidiarywill merge, subject to Vipont shareholder approval, into VipontPharmaceutical, and Vipont Pharmaceutical will become a whollyowned subsidiary of Colgate.   Vipont Pharmaceuticals reported $33.5 million in revenue and$4.5 million in net income for the fiscal year ended Sept. 30, 1988.</TEXT></DOC>